3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
16
Ovarian Neoplasms
9
Breast Neoplasms
9
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms, Unknown Primary
2
Neoplasms
2
NSCLC
2
Melanoma
2
Esophageal Neoplasms
2
Adenocarcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Docetaxel
70
Carboplatin
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
CP protocol
×
Clear all
NCT01404156
2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3
Completed
29 enrolled
NCT02924909
2018-03-20
QUIMERA
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
50 enrolled